Fetal renal abnormalities represent a significant proportion of structural anomalies detected during routine second-trimester prenatal sonography. While clinicians frequently attribute bilateral hyperechoic or cystic kidneys to polycystic kidney diseases or urinary tract obstructions, inborn errors of metabolism also demand diagnostic attention. Glutaric acidemia type II serves as a critical yet underrecognized etiology for severe fetal renal dysplasia. Early identification allows clinicians to provide timely genetic counseling and comprehensive reproductive guidance.

Clinical Presentation of Glutaric Acidemia Type II

Glutaric acidemia type II, also recognized as multiple acyl-CoA dehydrogenase deficiency, is an inherited autosomal recessive disorder of mitochondrial fatty acid and amino acid oxidation. Consequently, the defective electron transfer pathway impairs cellular energy production and leads to the accumulation of toxic organic acids. Clinicians classify this condition into three distinct clinical phenotypes based on neonatal presentation and the presence of structural malformations.

The most severe form, neonatal-onset type I, manifests with major congenital malformations and carries an extremely high mortality rate. In these cases, fetuses and neonates present with profound metabolic acidosis, nonketotic hypoglycemia, hyperammonemia, and fatal cardiomyopathy. In addition, affected infants frequently exhibit dysmorphic cranial features, rocker-bottom feet, and external genital abnormalities. Because symptoms progress rapidly after delivery, many neonates succumb within the first hours or days of life. Therefore, obstetricians and fetal medicine specialists must maintain a high index of suspicion whenever parents report previous unexplained neonatal deaths. Careful evaluation of parental consanguinity offers vital clues to the underlying autosomal recessive inheritance.

Sonographic Hallmarks and Fetal Renal Phenotypes

Ultrasonographic evaluation remains the primary modality for detecting fetal structural anomalies during the second trimester. In severe glutaric acidemia type II, prenatal imaging typically reveals enlarged, bilateral hyperechoic kidneys with microcystic cortical and medullary changes. Furthermore, sonographers often document altered corticomedullary differentiation and concurrent oligohydramnios due to compromised fetal renal perfusion.

However, these sonographic findings closely mirror primary renal developmental disorders, including autosomal recessive polycystic kidney disease and multicystic dysplastic kidney disease. In addition, syndromic ciliopathies such as Meckel-Gruber syndrome present with nearly identical hyperechoic renal architecture. Because these structural phenotypes overlap significantly, ultrasound alone cannot establish an unambiguous etiology. Clinicians must actively search for subtle systemic clues, such as intrahepatic biliary abnormalities or fetal growth restriction. Consequently, imaging specialists should treat isolated or complex renal cystic dysplasia as an indication for comprehensive genetic testing. Rapid and methodical investigation prevents diagnostic delay and provides clear prognostic answers to expectant parents.

Limitations of Standard Cytogenetics and Role of WES

Historically, diagnostic protocols for fetal malformations relied primarily on quantitative fluorescent polymerase chain reaction and chromosomal microarray analysis. While these conventional cytogenetic tools effectively identify chromosomal aneuploidies and substantial copy number variants, they completely miss single-nucleotide variants and small indels. Therefore, normal microarray results often provide false reassurance in fetuses with devastating monogenic metabolic disorders.

To overcome these diagnostic blind spots, maternal-fetal medicine teams increasingly utilize prenatal whole-exome sequencing. Indeed, exome sequencing systematically interrogates protein-coding regions across the nuclear genome, detecting causative point mutations and frameshift variants with remarkable accuracy. Furthermore, modern sequencing pipelines achieve rapid turnaround times, which is essential when clinicians face tight legal and gestational limits for reproductive decisions. In the evaluated case, standard molecular testing was normal, whereas exome sequencing quickly unmasked the underlying metabolic defect. Consequently, clinicians should consider whole-exome sequencing early when imaging demonstrates structural anomalies and standard genetic tests remain uninformative.

Pathophysiology of Novel ETFDH Frameshift Variants

At the molecular level, glutaric acidemia type II arises from pathogenic variants in three primary genes: ETFA, ETFB, and ETFDH. These genes encode the alpha subunit, beta subunit, and dehydrogenase component of the electron transfer flavoprotein complex, respectively. This critical mitochondrial enzyme transfer system shuttles electrons from multiple acyl-CoA dehydrogenases directly into the mitochondrial respiratory chain.

Specifically, pathogenic mutations in the ETFDH gene disrupt electron transfer flavoprotein ubiquinone oxidoreductase activity. The newly identified homozygous frameshift deletion, c.1200_1203del (p.His401GlnfsTer3), removes four nucleotides and shifts the open reading frame. Consequently, this mutation produces a premature termination codon that truncates the functional catalytic domain or triggers nonsense-mediated mRNA decay. As a result, cellular fatty acid beta-oxidation, amino acid catabolism, and choline oxidation cease functioning properly. Deprived of normal mitochondrial energy, renal tubular cells suffer membrane disruption and impaired tubulogenesis. Thus, progressive lipid accumulation and cellular dysfunction drive the development of extensive corticomedullary microcysts in developing fetal kidneys.

Implications for Genetic Counseling and Management

Establishing an accurate molecular diagnosis transforms reproductive counseling and clinical management for affected families. Because glutaric acidemia type II follows an autosomal recessive inheritance pattern, carrier parents face a 25 percent recurrence risk in every subsequent pregnancy. Furthermore, obtaining definitive genetic proof spares parents the uncertainty of empirical recurrence estimates and unhelpful diagnostic odysseys.

Once clinicians discover the specific familial pathogenic variant, they can offer targeted preimplantation genetic testing in future assisted reproductive cycles. Alternatively, parents may pursue early prenatal diagnosis through chorionic villus sampling or amniocentesis during future natural gestations. In addition, multidisciplinary counseling allows parents to understand the lethal prognosis associated with neonatal-onset glutaric acidemia type II. Armed with objective genomic evidence, families can make informed reproductive choices, including pregnancy termination or palliative comfort planning. Ultimately, integrating molecular genetics into fetal medicine ensures compassionate, precise, and family-centered clinical care.

Frequently Asked Questions

How does glutaric acidemia type II cause fetal renal cysts?

Glutaric acidemia type II impairs the electron transfer flavoprotein complex, which halts mitochondrial fatty acid oxidation and amino acid degradation. Consequently, toxic acyl-CoA intermediates and organic acids accumulate within renal tubular epithelial cells. This metabolic blockage depletes adenosine triphosphate, disrupts tubular membrane transport, and causes progressive cellular steatosis. As a result, the damaged tubules dilate into widespread microscopic cortical and medullary cysts during early fetal nephrogenesis.

When should clinicians order exome sequencing for fetal renal anomalies?

Clinicians should order prenatal whole-exome sequencing whenever ultrasound reveals unexplained bilateral hyperechoic or enlarged cystic kidneys, especially after normal microarray results. Furthermore, a family history of parental consanguinity, recurrent miscarriages, or unexplained neonatal deaths strongly justifies immediate genomic evaluation. Because early diagnosis guides critical reproductive counseling and pregnancy management, timely exome sequencing prevents unnecessary diagnostic delays and establishes the underlying monogenic etiology accurately.

What recurrence risk applies to couples carrying ETFDH mutations?

Couples carrying heterozygous pathogenic ETFDH mutations face a twenty-five percent risk of transmitting the condition to their offspring in each subsequent pregnancy. In addition, there is a fifty percent probability that a child will be an asymptomatic carrier, and a twenty-five percent chance of inheriting two normal alleles. Therefore, genetic counselors recommend targeted carrier screening, preimplantation genetic diagnosis, or early chorionic villus sampling for all future gestations.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Kaplan S et al. Prenatal diagnosis of severe glutaric acidemia type II due to a novel homozygous ETFDH frameshift variant: Case report and literature review. Turk J Obstet Gynecol. 2026 Oct 22. doi: 10.4274/tjod.galenos.2026.09552. PMID: 42902630.
2. Kucinska-Chahwan M, et al. Prenatal diagnosis of glutaric acidemia type 2 with the use of exome sequencing — an up-to-date review and new case report. Ginekol Pol. 2021;92(1):51-56.
3. Angle B, Burton BK. Risk of sudden death and acute life-threatening events in patients with glutaric acidemia type II. Mol Genet Metab. 2008;93(1):36-39.